~~<i id='FFA8269EA8'><strike id='FFA8269EA8'><tt id='FFA8269EA8'><pre id='FFA8269EA8'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-09-28 09:31:40 Page View：427

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Stephen Quake on the Chan Zuckerberg quest to conquer disease
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Curing rare childhood diseases will falter unless Congress steps up

AdobeWhenoursonPeterwasdiagnosedwithanultra-rareformofmusculardystrophyattheageof10,thefirstquestion

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Dems pitch expanding Medicare power to negotiate drug prices

Reps.RichardNeal(D-Mass.),Rep.FrankPallone(D-N.J.),andRep.JohnYarmuth(D-Ky.)JoeRaedle/GettyImagesWAS